Novartis to license cancer drug to low- and middle-income countries; how one pharma insider sees the drug pricing reform law

The deal with the Medicines Patent Pool marks the first time that a voluntary licensing deal has been arranged for a cancer medication. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries By Ed Silverman FABRICE COFFRINI/AFP/Getty Images The deal with the Medicines Patent Pool marks the first time that a voluntary licensing deal has been arranged for a cancer medication. Read More STAT+: How one pharma insider sees the drug pricing reform law: the impact will 'vary by product and by company' By Ed Silverman Charlie Neibergall/AP "At the end of the day, it’s a competitive market and you’ll still price as you would have," says former Gilead executive Jim Meyers. Read More Opinion: STAT+: What the Makena vote means about accelerated approval, trust, and the FDA By Mikkael A. Sekeres Sarah Silbiger/Getty Images The vote to pull Makena off the market is the right decision. But the FDA needs to better communicate why some drugs deserve this. Read More Sponsored Insight by Allucent Optimizing trial efficiency with Bayesian dose escalation designs As acceptance of flexible trial designs advances, sponsors are exploring alternate methods of dose escalation to support identification of a maximum tolerated dose (MTD). Selecting flexible dose escalation designs has the potential for a more precise determination of an MTD, increasing chances for trial success and patient safety. A blog from Allucent presents information about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives. Explore further. Opinion: Support family caregivers to improve and diversify clinical trials By Sharon Inouye and Jason Resendez Ben Margot/AP The clinical trial enterprise could reap numerous benefits from engaging family caregivers in studies if it engages them from the start. Read More Tuesday, October 25, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser